Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (201-210 of 1,124) with videos related to

Pageof 113
Sort By:
The Canadian Journal of Urology|January 13, 2006
Validation of prostate cancer index and SF-12 short formsThierry Lebeau, Paul Perrotte, Luc Valiquette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancerVincent Fradet, Laurent Lessard, Louis R Bégin, et al.
The Journal of Urology|June 17, 2008
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancerKim N Chi, Joseph L Chin, Eric Winquist, et al.
Cancer Medicine|October 25, 2013
Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsenBrent Blumenstein, Fred Saad, Sebastien Hotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2015
CD73 Expression Is an Independent Prognostic Factor in Prostate CancerBruno G Leclerc, Roxanne Charlebois, Guillaume Chouinard, et al.
The Prostate|September 21, 2011
ErbB2/Her-2 regulates the expression of Akt2 in prostate cancer cellsCécile Le Page, Ismaël Hervé Koumakpayi, Benjamin Péant, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 9, 2022
Assessment of the epidemiological trends for prostate cancer using administrative data in OntarioFred Saad, Bimal Bhindi, Krista Noonan, et al.
The Journal of Urology|March 15, 2018
A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local TherapyLaurence Klotz, Andrew Loblaw, Robert Siemens, et al.
The Canadian Journal of Urology|May 5, 2006
Therapeutic approach to hormone-refractory prostate cancerFred Saad, Abdulhadi Al Dejmah, Paul Perrotte, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 31, 2007
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancerVenita DePuy, Kevin J Anstrom, Liana D Castel, et al.
Pageof 113

Showing results (201-210 of 1,124) with videos related to

Sort By:
Pageof 113
The Canadian Journal of Urology|January 13, 2006
Validation of prostate cancer index and SF-12 short formsThierry Lebeau, Paul Perrotte, Luc Valiquette, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2004
Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancerVincent Fradet, Laurent Lessard, Louis R Bégin, et al.
The Journal of Urology|June 17, 2008
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancerKim N Chi, Joseph L Chin, Eric Winquist, et al.
Cancer Medicine|October 25, 2013
Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsenBrent Blumenstein, Fred Saad, Sebastien Hotte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 9, 2015
CD73 Expression Is an Independent Prognostic Factor in Prostate CancerBruno G Leclerc, Roxanne Charlebois, Guillaume Chouinard, et al.
The Prostate|September 21, 2011
ErbB2/Her-2 regulates the expression of Akt2 in prostate cancer cellsCécile Le Page, Ismaël Hervé Koumakpayi, Benjamin Péant, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|December 9, 2022
Assessment of the epidemiological trends for prostate cancer using administrative data in OntarioFred Saad, Bimal Bhindi, Krista Noonan, et al.
The Journal of Urology|March 15, 2018
A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local TherapyLaurence Klotz, Andrew Loblaw, Robert Siemens, et al.
The Canadian Journal of Urology|May 5, 2006
Therapeutic approach to hormone-refractory prostate cancerFred Saad, Abdulhadi Al Dejmah, Paul Perrotte, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 31, 2007
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancerVenita DePuy, Kevin J Anstrom, Liana D Castel, et al.
Pageof 113